MX2008012666A - Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos. - Google Patents

Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.

Info

Publication number
MX2008012666A
MX2008012666A MX2008012666A MX2008012666A MX2008012666A MX 2008012666 A MX2008012666 A MX 2008012666A MX 2008012666 A MX2008012666 A MX 2008012666A MX 2008012666 A MX2008012666 A MX 2008012666A MX 2008012666 A MX2008012666 A MX 2008012666A
Authority
MX
Mexico
Prior art keywords
amylin
seq
disorder
disorders
psychiatric
Prior art date
Application number
MX2008012666A
Other languages
English (en)
Spanish (es)
Inventor
David G Parkes
Andrew A Young
Kevin D Laugero
Michael Hanley
Christine Mack
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of MX2008012666A publication Critical patent/MX2008012666A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2008012666A 2006-03-31 2006-10-04 Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos. MX2008012666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (1)

Publication Number Publication Date
MX2008012666A true MX2008012666A (es) 2008-10-13

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012666A MX2008012666A (es) 2006-03-31 2006-10-04 Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.

Country Status (7)

Country Link
EP (1) EP2010208A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009538824A (cg-RX-API-DMAC7.html)
KR (1) KR20080106950A (cg-RX-API-DMAC7.html)
AU (1) AU2006341375B2 (cg-RX-API-DMAC7.html)
CA (1) CA2647568A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012666A (cg-RX-API-DMAC7.html)
WO (1) WO2007114838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
WO2009043469A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of pneumadin as a therapeutic agent
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー/エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
JP2013511287A (ja) 2009-11-23 2013-04-04 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー ポリペプチド・コンジュゲート
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2108122T3 (es) * 1991-05-24 1997-12-16 Amylin Pharmaceuticals Inc Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
EP1750752A2 (en) * 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
KR20080003849A (ko) * 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법

Also Published As

Publication number Publication date
CA2647568A1 (en) 2007-10-11
WO2007114838A1 (en) 2007-10-11
AU2006341375A1 (en) 2007-10-11
EP2010208A1 (en) 2009-01-07
AU2006341375B2 (en) 2013-03-21
JP2009538824A (ja) 2009-11-12
KR20080106950A (ko) 2008-12-09
AU2006341375A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
US7671023B2 (en) Amylin agonist for treating depression, anxiety disorder and schizophrenia
CN101094689B (zh) 治疗肥胖以及肥胖相关疾病和病症的方法
US20100004166A1 (en) Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
JP2011527309A (ja) 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
US7666833B2 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
US20100256061A1 (en) Gastrin compound for diabetes treatment
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
MX2007005274A (en) Methods for treating obesity and obesity related diseases and disorders

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status